Christoph F. Ebenbichler

Innsbruck, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Journal: Circulation
Published: May 25, 2026

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Journal: Circulation
Published: May 19, 2026

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Journal: Circulation
Published: May 19, 2026

Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria.

Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria.

Journal: Journal of clinical lipidology
Published: January 16, 2026

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.

Journal: JAMA cardiology
Published: September 13, 2023

Filling the gap: Genetic risk assessment in hypercholesterolemia using LDL-C and LPA genetic scores.

Filling the gap: Genetic risk assessment in hypercholesterolemia using LDL-C and LPA genetic scores.

Journal: Clinical genetics
Published: March 22, 2023

Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.

Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.

Journal: Wiener klinische Wochenschrift
Published: March 01, 2023

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.

Journal: Wiener klinische Wochenschrift
Published: January 11, 2023

Mental disorders and diabetes mellitus (Update 2023)

Mental disorders and diabetes mellitus (Update 2023)

Journal: Wiener klinische Wochenschrift
Published: November 09, 2022

Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.

Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.

Journal: Atherosclerosis
Published: September 13, 2022

Bariatric surgery prevents carotid wall thickness progression.

Bariatric surgery prevents carotid wall thickness progression.

Journal: Wiener klinische Wochenschrift
Published: April 02, 2022

Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.

Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.

Journal: Atherosclerosis
Published: December 10, 2021
Showing 1-12 of 44

Last Updated: 09/26/2026